A Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound (SSPE)

This study is currently recruiting participants.
Verified December 2012 by Ottawa Hospital Research Institute
Sponsor:
Information provided by (Responsible Party):
Marc Carrier, MD, Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT01455818
First received: October 18, 2011
Last updated: December 7, 2012
Last verified: December 2012

October 18, 2011
December 7, 2012
March 2011
Not Provided
Recurrent VTE [ Time Frame: 90 day follow-up ] [ Designated as safety issue: Yes ]
Recurrent VTE will be diagnosed according to previously published criteria: 1)Lower extremity US revealing non-compressibility at the trifurcation of the popliteal vein or above; OR 2) Venography demonstrating a constant intraluminal filling defect above the trifurcation of the popliteal vein; OR 3) Pulmonary angiography demonstrating a new constant intraluminal filling defect or a cut off of a vessel; OR 4) Ventilation/perfusion scanning with a high probability of PE; OR 5) CTPA demonstrating new intraluminal filling defect in a subsegmental or greater sized pulmonary artery; OR 6) PE discovered at autopsy.
Not Provided
Complete list of historical versions of study NCT01455818 on ClinicalTrials.gov Archive Site
  • Interobserver agreement for SSPE diagnosis on CTPA (local Vs. central interpretation) [ Time Frame: 90 day follow-up ] [ Designated as safety issue: Yes ]
  • Death due to PE [ Time Frame: 90 day follow-up ] [ Designated as safety issue: Yes ]
    Definition of death due to PE Certain: hypotension, hypoxia, cardiac arrest with no other explanation other than PE and autopsy or radiographic confirmation Highly probable: criteria for certain but another disease could have caused the death Probable: other cause suspected based on clinical evidence but 100% certainty not available Unlikely: all other cases
  • Death probably due to PE [ Time Frame: 90 day follow-up ] [ Designated as safety issue: Yes ]
    Certain: hypotension, hypoxia, cardiac arrest with no other explanation other than PE and autopsy or radiographic confirmation Highly probable: criteria for certain but another disease could have caused the death Probable: other cause suspected based on clinical evidence but 100% certainty not available Unlikely: all other cases
  • Major bleeding [ Time Frame: 90 day follow-up ] [ Designated as safety issue: Yes ]

    Major bleeding will be defined according to previously published criteria (51):

    1. Fatal bleeding; OR
    2. Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome; OR
    3. Bleeding causing a fall in hemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells
  • Minor bleeding [ Time Frame: 90 day follow-up ] [ Designated as safety issue: Yes ]
    Minor bleeding will be defined as any bleeding not meeting the requirements of a major bleeding event.
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound
A Multicenter Prospective Cohort Management Study to Evaluate the Safety of Withholding Anticoagulation in Patients With Subsegmental PE Who Have a Negative Serial Bilateral Lower Extremity Ultrasound

Blood clots in lung arteries (pulmonary embolism) are usually detected using a radiological test called computed tomography (CT scan). As technology advances, the CT scans are able to detect smaller and smaller blood clots. Over time, the frequency of blood clots in the pulmonary arteries has increased significantly (CT scan are now detecting very small blood clots that the investigators could not see before). As a result, more and more people are on blood thinners to treat these small blood clots but their true clinical significance is unknown.

The management of blood thinners is costly and also utilizes scarce healthcare resources. These blood thinners need to be monitored with frequent blood work. Furthermore, every year, approximately 3 percent of patients on blood thinners will have a major bleeding event requiring medical attention.

The investigators don't think that treating these small blood clots in the pulmonary arteries detected on CT scan is worth the risk of bleeding from the blood thinners.

The main goal of this study is to find out if it is safe to not treat very small blood clots in the pulmonary arteries.

The investigators plan to follow 270 patients with small blood clots in their lungs for 90 days. These patients will not be treated with blood thinners but will be followed closely with other non-invasive tests to avoid progression or recurrence of blood clots.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Consecutive patients with symptomatic, isolated SSPE* (any number), that are newly diagnosed by computed tomographic pulmonary angiography will be eligible to participate in the study.

Subsegmental (Single or Multiple) Pulmonary Embolism
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
Not Provided
Not Provided

Inclusion Criteria:

Patients with newly diagnosed isolated SSPE* (any number) that are managed as outpatients will be eligible to participate in the study.

*Isolated SSPE is defined as CTPA demonstrating an intraluminal filling defect in a subsegmental artery with no filling defects visualized at more proximal pulmonary artery levels.

Exclusion Criteria:

  1. Proximal lower extremity (popliteal vein or above) or upper extremity (subclavian vein or above) DVT.
  2. Need for long term oral anticoagulant therapy for reasons other than VTE.
  3. Hospitalized at the time of SSPE diagnosis or admitted to hospital with SSPE diagnosis.
  4. Requiring oxygen therapy to maintain an O2 saturation over 92%
  5. Previous history of DVT or PE
  6. Geographically inaccessible for follow-up
  7. Active Malignancy (defined as other than basal-cell or squamous cell carcinoma of the skin; cancer within the past 6 months; any treatment for cancer in the past 6 months; or recurrent or metastatic cancer)
  8. Pregnancy (or within 6 weeks postpartum)
  9. Have received more than 48 hours of anticoagulants
  10. Unable/refuse to sign informed consent
  11. Asymptomatic SSPE (e.g. SSPE is an incidental finding on a CT scan conducted for reasons other than suspected PE)
Both
18 Years and older
No
Contact: Bruno Lemire, PhD (c) 613-737-8899 ext 72998 blemire@ohri.ca
Contact: Amanda Pecarskie, RN 613-798-5555 ext 18932 apecarskie@ohri.ca
Canada,   France,   Switzerland
 
NCT01455818
2009600-01H
Yes
Marc Carrier, MD, Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Not Provided
Not Provided
Ottawa Hospital Research Institute
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP